



COVID-19 Response + Recovery

Cross-Functional Team Update

8.2.21

Table of Contents

1. Overview (Tommy Gonzalez)
2. Team Lead Report:
 - a) Health Focus (Hector Ocaranza, M.D.)
3. City Manager Wrap-up (Tommy Gonzalez)



1. Overview

Tommy Gonzalez




3. Team Lead Report



a. Health Focus


Hector I. Ocaranza, M.D.

COVID-19 Summary




- ❖ We are experiencing an upward trend of new cases
- ❖ During June cases remain stable Avg 2.1 cases/100,000 (1.2-3.0) up until 2nd week of July when cases are increasing
- ❖ Total number of new cases in July doubled those from June
- ❖ Last 3 weeks 7-day avg of new cases per capita have grown 2.5 times
- ❖ 82-92% of new cases were unvaccinated

New Cases June/July




Age Distribution Cases




COVID-19 Hospitalizations

- ❖ Number of people hospitalized in June decreased and July has seen an increase
- ❖ 90% of new admissions were unvaccinated
- ❖ We continue to build our protection and have vaccinated 7 out of 10 people in our community so far.





COVID-19 (delta variant)



General Aspects

- Delta variant (B.1.617.2) First identified in India December 2020
- Most common variant in India April 2021
- Delta variant identified by spike protein mutations
- This variant is more infectious and concerning than original virus due to:
 - Increased Transmission
 - Higher affinity to human body receptors
 - Replicates faster and expresses larger amounts of viral load
 - Symptomatic disease sooner
 - Potential to escape immune system

COVID-19 (delta variant)



COVID-19 (delta variant)

- ❖ Symptoms for delta variant are what we know about COVID-19 but may present with:
 - Sore throat, Headache, GI symptoms
- ❖ Treatment:
 - No different as any other COVID-19 patient
- ❖ Vaccine effectiveness Pfizer-BioNTech against delta variant:
 - 1-dose: 35.6% (22.7-46.4)
 - 2-dose: 88.0 % (85.3-90.1)



4. City Manager Wrap Up

Tommy Gonzalez



Thank you!